![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SH3RF2 |
Gene summary for SH3RF2 |
![]() |
Gene information | Species | Human | Gene symbol | SH3RF2 | Gene ID | 153769 |
Gene name | SH3 domain containing ring finger 2 | |
Gene Alias | HEPP1 | |
Cytomap | 5q32 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q08AM8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
153769 | SH3RF2 | CCI_2 | Human | Cervix | CC | 2.19e-06 | 7.06e-01 | 0.5249 |
153769 | SH3RF2 | CCI_3 | Human | Cervix | CC | 5.78e-14 | 8.56e-01 | 0.516 |
153769 | SH3RF2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.43e-28 | -6.73e-01 | 0.0155 |
153769 | SH3RF2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.54e-02 | -7.11e-01 | 0.0216 |
153769 | SH3RF2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.31e-11 | 6.13e-01 | -0.1954 |
153769 | SH3RF2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.32e-02 | -6.82e-01 | -0.2196 |
153769 | SH3RF2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.55e-09 | -6.54e-01 | -0.1207 |
153769 | SH3RF2 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.11e-15 | -6.56e-01 | 0.096 |
153769 | SH3RF2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 7.92e-03 | -6.47e-01 | 0.0451 |
153769 | SH3RF2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 5.02e-04 | -6.09e-01 | 0.0528 |
153769 | SH3RF2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 9.32e-03 | -4.90e-01 | 0.0338 |
153769 | SH3RF2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.75e-07 | -4.92e-01 | 0.0674 |
153769 | SH3RF2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 4.45e-06 | -5.01e-01 | 0.0112 |
153769 | SH3RF2 | HTA11_11156_2000001011 | Human | Colorectum | AD | 4.95e-04 | -9.90e-01 | 0.0397 |
153769 | SH3RF2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.46e-03 | -4.80e-01 | 0.0588 |
153769 | SH3RF2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.17e-31 | -7.30e-01 | 0.294 |
153769 | SH3RF2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.54e-28 | -7.37e-01 | 0.3859 |
153769 | SH3RF2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.81e-05 | -5.82e-01 | 0.2585 |
153769 | SH3RF2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.68e-64 | -1.13e+00 | 0.3005 |
153769 | SH3RF2 | F007 | Human | Colorectum | FAP | 1.22e-12 | -7.49e-01 | 0.1176 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005140317 | Oral cavity | LP | stress-activated MAPK cascade | 84/4623 | 239/18723 | 1.79e-04 | 2.00e-03 | 84 |
GO:007030216 | Oral cavity | LP | regulation of stress-activated protein kinase signaling cascade | 68/4623 | 195/18723 | 8.92e-04 | 7.64e-03 | 68 |
GO:003287216 | Oral cavity | LP | regulation of stress-activated MAPK cascade | 66/4623 | 192/18723 | 1.60e-03 | 1.23e-02 | 66 |
GO:003287316 | Oral cavity | LP | negative regulation of stress-activated MAPK cascade | 22/4623 | 51/18723 | 2.96e-03 | 2.03e-02 | 22 |
GO:007030316 | Oral cavity | LP | negative regulation of stress-activated protein kinase signaling cascade | 22/4623 | 51/18723 | 2.96e-03 | 2.03e-02 | 22 |
GO:005186512 | Oral cavity | LP | protein autoubiquitination | 29/4623 | 73/18723 | 3.20e-03 | 2.18e-02 | 29 |
GO:004217628 | Skin | AK | regulation of protein catabolic process | 101/1910 | 391/18723 | 4.78e-19 | 9.43e-16 | 101 |
GO:190336228 | Skin | AK | regulation of cellular protein catabolic process | 72/1910 | 255/18723 | 3.99e-16 | 1.97e-13 | 72 |
GO:190305028 | Skin | AK | regulation of proteolysis involved in cellular protein catabolic process | 61/1910 | 221/18723 | 2.17e-13 | 6.12e-11 | 61 |
GO:200005828 | Skin | AK | regulation of ubiquitin-dependent protein catabolic process | 50/1910 | 164/18723 | 5.25e-13 | 1.41e-10 | 50 |
GO:190332028 | Skin | AK | regulation of protein modification by small protein conjugation or removal | 62/1910 | 242/18723 | 4.90e-12 | 1.04e-09 | 62 |
GO:003243428 | Skin | AK | regulation of proteasomal ubiquitin-dependent protein catabolic process | 41/1910 | 134/18723 | 5.64e-11 | 1.01e-08 | 41 |
GO:001049827 | Skin | AK | proteasomal protein catabolic process | 97/1910 | 490/18723 | 9.65e-11 | 1.54e-08 | 97 |
GO:003139628 | Skin | AK | regulation of protein ubiquitination | 54/1910 | 210/18723 | 9.94e-11 | 1.55e-08 | 54 |
GO:006113628 | Skin | AK | regulation of proteasomal protein catabolic process | 50/1910 | 187/18723 | 1.09e-10 | 1.66e-08 | 50 |
GO:004573228 | Skin | AK | positive regulation of protein catabolic process | 57/1910 | 231/18723 | 1.72e-10 | 2.49e-08 | 57 |
GO:003139728 | Skin | AK | negative regulation of protein ubiquitination | 30/1910 | 83/18723 | 2.29e-10 | 3.01e-08 | 30 |
GO:004316127 | Skin | AK | proteasome-mediated ubiquitin-dependent protein catabolic process | 84/1910 | 412/18723 | 3.96e-10 | 4.88e-08 | 84 |
GO:190332128 | Skin | AK | negative regulation of protein modification by small protein conjugation or removal | 32/1910 | 95/18723 | 4.71e-10 | 5.26e-08 | 32 |
GO:190336428 | Skin | AK | positive regulation of cellular protein catabolic process | 43/1910 | 155/18723 | 6.24e-10 | 6.48e-08 | 43 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SH3RF2 | SNV | Missense_Mutation | c.742G>A | p.Glu248Lys | p.E248K | Q8TEC5 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SH3RF2 | SNV | Missense_Mutation | rs139468138 | c.2075N>A | p.Arg692Gln | p.R692Q | Q8TEC5 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BH-A42T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SH3RF2 | SNV | Missense_Mutation | novel | c.359T>C | p.Val120Ala | p.V120A | Q8TEC5 | protein_coding | tolerated(0.46) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SH3RF2 | SNV | Missense_Mutation | rs747775775 | c.1306N>A | p.Val436Ile | p.V436I | Q8TEC5 | protein_coding | deleterious(0.02) | benign(0.144) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
SH3RF2 | SNV | Missense_Mutation | rs747678660 | c.1585G>A | p.Gly529Arg | p.G529R | Q8TEC5 | protein_coding | tolerated(0.07) | benign(0.031) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
SH3RF2 | SNV | Missense_Mutation | c.1516C>A | p.Gln506Lys | p.Q506K | Q8TEC5 | protein_coding | deleterious(0.01) | benign(0.156) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
SH3RF2 | SNV | Missense_Mutation | rs757233835 | c.496N>A | p.Glu166Lys | p.E166K | Q8TEC5 | protein_coding | deleterious(0.02) | probably_damaging(0.936) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SH3RF2 | SNV | Missense_Mutation | c.2039N>T | p.Ser680Phe | p.S680F | Q8TEC5 | protein_coding | tolerated(0.61) | benign(0.048) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SH3RF2 | SNV | Missense_Mutation | novel | c.935N>C | p.Val312Ala | p.V312A | Q8TEC5 | protein_coding | deleterious(0.05) | probably_damaging(0.918) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SH3RF2 | SNV | Missense_Mutation | rs753470880 | c.1696G>A | p.Val566Met | p.V566M | Q8TEC5 | protein_coding | tolerated(0.25) | benign(0.005) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |